Table 4.
Multiple Regression Analyses of Cardiovascular Mortality Without and With Censoring at Time of Salvage GnRH Agonist Therapy (N = 945 using imputed missing values)
| Covariate | Without Censoring
|
With Censoring
|
||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Treatment arm: arm 2 v arm 1 | 0.76 | 0.52 to 1.09 | .14 | 0.97 | 0.63 to 1.48 | .88 |
| Age: < 70 v ≥ 70 years | 1.59 | 1.04 to 2.42 | .032 | 1.47 | 0.91 to 2.37 | .12 |
| Prevalent CVD: no v yes | 2.70 | 1.84 to 3.95 | < .0001 | 2.97 | 1.91 to 4.60 | < .0001 |
| Prevalent HTN: no v yes | 1.09 | 0.75 to 1.58 | .67 | 1.15 | 0.75 to 1.74 | .53 |
| Prevalent DM: no v yes | 1.79 | 1.10 to 2.89 | .018 | 1.83 | 1.07 to 3.12 | .027 |
| BMI, kg/m2 | ||||||
| < 25 | — | — | — | — | ||
| ≥ 25 to < 30 | 1.10 | 0.71 to 1.70 | .68 | 1.07 | 0.64 to 1.79 | .81 |
| ≥ 30 | 1.09 | 0.62 to 1.92 | .80 | 1.21 | 0.63 to 2.32 | .57 |
| Race: black v other | 0.86 | 0.47 to 1.55 | .60 | 1.25 | 0.58 to 2.69 | .57 |
| Prostatectomy: no v yes | 0.77 | 0.30 to 1.98 | .59 | 0.61 | 0.20 to 1.86 | .38 |
| Nodal involvement: no v yes | 1.17 | 0.68 to 2.02 | .57 | 0.88 | 0.46 to 1.70 | .71 |
| Acid phosphatase: not elevated v elevated | 1.01 | 0.68 to 1.51 | .96 | 1.10 | 0.70 to 1.74 | .67 |
| Gleason score | ||||||
| 2-6 | — | — | — | — | ||
| 7 | 0.94 | 0.61 to 1.46 | .80 | 0.80 | 0.48 to 1.31 | .37 |
| 8-10 | 0.82 | 0.50 to 1.35 | .43 | 0.74 | 0.41 to 1.34 | .32 |
| Clinical stage: A/B v C | 1.67 | 0.80 to 3.45 | .17 | 1.11 | 0.49 to 2.54 | .80 |
Abbreviations: GnRH, gonadotropin-releasing hormone; HR, hazard ratio; CVD, cardiovascular disease; HTN, hypertension; DM, diabetes mellitus; BMI, body mass index.